ARTICLE | Clinical News
Cortex, Shire begin Phase II for SPD420
June 13, 2001 7:00 AM UTC
COR and partner Shire (LSE:SHP; SHPGY) will begin a placebo-controlled U.S. Phase II study of COR's SPD420 Ampakine glutamate receptor modulator (formerly CX516) in 114 adult patients with attention d...